Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 3.8% – Time to Sell?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s stock price traded down 3.8% on Monday . The stock traded as low as $20.55 and last traded at $20.52. 29,466 shares changed hands during mid-day trading, a decline of 87% from the average session volume of 226,296 shares. The stock had previously closed at $21.33.

Analyst Ratings Changes

Several research analysts have commented on the stock. Raymond James upgraded shares of Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. Guggenheim reissued a “buy” rating and issued a $84.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Wedbush reaffirmed an “outperform” rating and set a $36.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. TD Cowen started coverage on Dianthus Therapeutics in a research note on Friday, December 20th. They issued a “buy” rating for the company. Finally, HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $52.14.

Dianthus Therapeutics Stock Performance

The stock’s fifty day simple moving average is $22.54 and its two-hundred day simple moving average is $24.81. The company has a market capitalization of $625.24 million, a price-to-earnings ratio of -8.55 and a beta of 1.82.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.04. The business had revenue of $1.33 million during the quarter, compared to analyst estimates of $1.40 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. On average, equities analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of large investors have recently made changes to their positions in DNTH. Woodline Partners LP grew its position in Dianthus Therapeutics by 20.0% during the 4th quarter. Woodline Partners LP now owns 300,504 shares of the company’s stock worth $6,551,000 after purchasing an additional 50,000 shares in the last quarter. Vestal Point Capital LP grew its holdings in shares of Dianthus Therapeutics by 172.2% during the fourth quarter. Vestal Point Capital LP now owns 1,075,000 shares of the company’s stock valued at $23,435,000 after buying an additional 680,000 shares in the last quarter. Octagon Capital Advisors LP raised its position in Dianthus Therapeutics by 20.8% during the fourth quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company’s stock valued at $46,002,000 after buying an additional 363,500 shares during the period. Millennium Management LLC lifted its stake in Dianthus Therapeutics by 160.2% in the 4th quarter. Millennium Management LLC now owns 90,436 shares of the company’s stock worth $1,972,000 after acquiring an additional 55,682 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its holdings in shares of Dianthus Therapeutics by 14.4% during the fourth quarter. Janus Henderson Group PLC now owns 1,085,648 shares of the company’s stock worth $23,607,000 after purchasing an additional 136,314 shares during the period. Institutional investors and hedge funds own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.